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The phosphoinositide 5-kinase (PIKfyve) is a critical
enzyme for the synthesis of PtdIns(3,5)P2,t h a th a s
been implicated in various trafﬁcking events associ-
ated with the endocytic pathway. We have now directly
compared the effects of siRNA-mediated knockdown
of PIKfyve in HeLa cells with a speciﬁc pharmaco-
logical inhibitor of enzyme activity. Both approaches
induce changes in the distribution of CI-M6PR and
trans-Golgi network (TGN)-46 proteins, which cycles
between endosomes and TGN, leading to their accu-
mulation in dispersed punctae, whilst the TGN marker
golgin-245 retains a perinuclear disposition. Trafﬁck-
ing of CD8-CI-M6PR (retromer-dependent) and CD8-Furin
(retromer-independent) chimeras from the cell surface
to the TGN is delayed following drug administration,
as is the transport of the Shiga toxin B-subunit. siRNA
knockdown of PIKfyve produced no defect in epider-
mal growth factor receptor (EGFR) degradation, unless
combined with knockdown of its activator molecule
Vac14, suggesting that a low threshold of PtdIns(3,5)P2
is necessary and sufﬁcient for this pathway. Accord-
ingly pharmacological inhibition of PIKfyve results in a
profound block to the lysosomal degradation of acti-
vated epidermal growth factor (EGF) and Met recep-
tors. Immunoﬂuorescence revealed EGF receptors to
be trapped in the interior of a swollen endosomal
compartment. In cells starved of amino acids, PIKfyve
inhibition leads to the accumulation of the lipidated
form of GFP-LC3, a marker of autophagosomal struc-
tures, which can be visualized as ﬂuorescent punctae.
We suggest that PIKfyve inhibition may render the late
endosome/lysosome compartment refractory to fusion
with both autophagosomes and with EGFR-containing
multivesicular bodies.
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3-phosphoinositides control the identity and dynamics
of endocytic compartments, through the recruitment of
multiple effector proteins containing speciﬁc recognition
domains. PtdIns3P is generated by the class III PtdIns
3-kinase, hVps34, and is concentrated on early/sorting
endosomes (1). It is required for receptor trafﬁcking (2)
and membrane fusion events (3), through its contribution
to recruitment of several proteins containing FYVE or
phox homology phox homology (PX) domains. The FYVE
domain proteins early endosomal autoantigen-1 (EEA1)
and hepatocyte growth factor regulated tyrosine kinase
substrate (Hrs) are required for endosome fusion and
receptor sorting respectively (4,5), whilst the PX domain
containing Sorting Nexin 1 (SNX1) is a component of the
retromer complex that mediates retrieval of the cation-
independent mannose-6-phosphate receptor (CI-M6PR)
from the endocytic pathway to the trans-Golgi network
(TGN) (6).
PtdIns3P is also a precursor for the generation of
PtdIns(3,5)P2 by the FYVE domain containing PtdIns 5-
kinase, PIKfyve (7,8). The enzyme was ﬁrst linked to the
endosomal pathway by the observation that deletion of
the yeast homologue results in markedly swollen vacuoles
(9). Levels of PtdIns(3,5)P2 increase due to various
stresses, osmotic shock in yeast (10) and ultraviolet (UV)
radiation in mammalian cells (11). In yeast and mammalian
cells PIKfyve interaction with Vac14 serves to stimulate
enzymatic activity (12–14).
Identiﬁcation of bone ﬁde effectors of PtdIns(3,5)P2
has proven elusive (15). The best established is the
yeast protein Svp1/Atg18, for which deletion results
in a swollen vacuole phenotype (16). The mammalian
homologues of Svp1 are the WD repeat domain
containing, phosphoinositide-interacting 1 (WIPI-1) and
WIPI-2 proteins. WIPI-1 (also known as WIPI-49) binds
to PtdIns3P and PtdIns(3,5)P2, and altering its expression
levels leads to changes in the distribution of CI-M6PR (17).
Svp1/Atg18 was identiﬁed in a screen for yeast autophagy
genes (18) and WIPI-1 has also been shown to associate
with starvation-induced autophagic vacuoles (19).
Various studies have examined the effects of manipulat-
ing PIKfyve and Vac14 levels. A Caenorhabditis elegans
(C. elegans) mutant hypomorphic for the PIKfyve homo-
logue was suggested to possess a defect in retrieval
of membrane from mature lysosomes (20). Deletion of
Drosophila PIKfyve yields cells with enlarged endosomes
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and a defect in degradation of Wingless and Notch, with-
out any apparent signalling defects (21). Vac14 −/− mice
show a neurodegenerative defect, whilst at the cellular
level, both large vacuoles and trapping of the CI-M6PR in
endosomal compartments are evident (22). siRNA knock-
down of PIKfyve is only partially effective, but also leads
to defects in CI-M6PR trafﬁcking whilst the degradation
of epidermal growth factor receptor (EGFR) is unaffected
(23).
Jefferieset al.haverecentlycharacterizedanovel inhibitor
of PIKfyve, YM201636, which provides the ﬁrst opportu-
nity for acute inhibition of the enzyme (24). This can allow
discrimination of direct effects due to enzyme inhibition
rather than longer-term adaptive responses of cells to
knockout, or of protein functions unconnected to enzy-
matic activity. We now provide further characterization of
the cellular effects of a PIKfyve inhibitor (MF4) pharma-
cologically similar to YM201636, which we have directly
compared with knockdown of PIKfyve alone or in com-
bination with Vac14. Our data reveal acute effects upon
receptor tyrosine kinase (RTK) trafﬁcking that reconcile
with observations from model organisms, and provide
new insight into PIKfyve involvement in cycling between
TGN and endosomes as well as the autophagy pathway.
Results
PIKfyve inhibition creates swollen vacuoles
inaccessible to ﬂuid phase marker
Knockdown of PIKfyve in HeLa cells creates swollen
vacuoles visible by phase contrast light microscopy in
∼30%ofcellsaspreviouslyreported(23).We could obtain
highly efﬁcient knockdown of the PIKfyve activator protein
Vac14 but this only produced the vacuole phenotype at
verylowpenetrance(∼3%)anddidnotaugmenttheeffect
of PIKfyve knockdown on vacuole formation (not shown).
MF4ischemicallysimilartotherecentlydescribedspeciﬁc
PIKfyve inhibitor YM201636 by Jefferies et al., with the
only difference being that MF4 lacks an amino group on
the pyridine ring (24), (Figure 1E). MF4 inhibited PIKfyve
with an IC50 of 23 nM, whereas an inactive analogue
MF2 showed no activity even at 5 μM. Corresponding
MF4 values for class I PtdIns 3-kinases which we
determined are 0.25 μM (p110α), 1 μM (p110β), 0.9 μM
(p110γ)a n d0 .8 μM (p110δ). Application of MF4 gives
a vacuolar phenotype in all cells within 4 h. Electron
microscopic analysis indicates that the large phase lucent
vacuoles are inaccessible to internalized horseradish
peroxidase (HRP), but they do become surrounded by a
second class of smaller (but still swollen) HRP-containing
vacuoles, positive for early (EEA1) or late endosomal
markers [lysosome-associated membrane protein (LAMP-
2)] (Figure 1A and B), which we will henceforth refer
to as ’swollen endosomes’. The retromer components
Vps26 and SNX1 also associate with swollen endosomal
structures (Figure 1C).MF4 does not appreciably reduce
cellular PtdIns3P levels or its cellular distribution, as
assessed by immunoﬂuorescence labelling of cells for
this lipid with a GST-2xFYVE probe (Figure 1D).
Disruption of endosome to TGN trafﬁcking
PIKfyve has been implicated in the control of the retromer-
mediated pathway between endosomes and the TGN
through siRNA studies of CI-M6PR distribution with
respect to the marker protein TGN-46 (23). Certain
aspects of these studies may be complicated by the
fact that TGN-46 itself undergoes a cycling itinerary,
which partially overlaps with ciM6PR (25). We have
now analyzed the steady-state distribution of TGN-46,
CI-M6PR and golgin-245 following individual knockdown
of PIKfyve, hVac14, a combination of the two and the
PIKfyve inhibitor. Knockdown of PIKfyve or its inhibition
leads to a more dispersed distribution of CI-M6PR but
also of TGN-46, whilst knockdown of Vac14 has little
effect (Figure 2A and B). In cells where the TGN46 has
been highly dispersed, there is little co-localization with
CI-M6PR or with an alternative TGN marker golgin-245
(26),whichretainsitscharacteristicperinuclearlocalization
(Figure 2C). Under conditions where TGN-46 is highly
dispersed, the cis-Golgi marker GM130 retains its ribbon-
like disposition (Figure 2D), characteristic of intact Golgi
structure. No changes in levels of CI-M6PR or of retromer
components are seen as a consequence of PIKfyve
inhibition (Figure 2E).
Cell surface exposed CI-M6PR can be retrieved to the
TGN following endocytosis, and Shiga toxin follows an
overlapping retromer-dependent route (27). We have
followed trafﬁcking of a chimeric CD8-CI-M6PR along
this route following application of an anti-CD8 antibody
and of ﬂuorescently labelled Shiga toxin B-subunit.
Furthermore, we have followed the trafﬁcking of a
CD8-Furin chimeric protein, which also trafﬁcs from the
cell surface to the TGN, but in a retromer-independent
fashion (28). Following PIKfyve inhibition, internalized
CD8-CI-M6PR and CD8-Furin both can reach a TGN
compartment, but show slower rates of accumulation
at this perinuclear destination (Figure 3A). In cells
which show highly dispersed TGN-46 punctae, these
do not co-localize with CD8-CI-M6PR at the ﬁnal time-
point (Figure 3B). Shiga toxin can reach the perinuclear
TGN as judged by co-localization with golgin-245,
(Figure 4A and B) following PIKfyve inhibition, but its
accumulation there, is impeded and co-localization with
dispersed TGN-46 positive punctae can also be observed
(Figure 4C).
Downregulation of RTKs
PIKfyve siRNA studies of EGF-induced EGFR downreg-
ulation have not revealed any defect in EGFR down-
regulation (23). Our data concur with these previous
studies, but we noticed that when combined with Vac14
knockdown a modest defect in EGFR downregulation is
evident (Figure 5A and B). A far more effective block to
EGFR and also c-Met downregulation was seen following
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Figure 1: PIKfyve inhibition creates large swollen vacuoles inaccessible to ﬂuid phase marker. HeLa cells were treated with
800 nM PIKfyve inhibitor (MF4) for 4 h prior to either ﬁxation and staining with a variety of markers by immunoﬂuorescence, or uptake
of HRP for 1 h, ﬁxation and processing for EM (see Materials and Methods for details). Wortmannin was added to cells at 100 nM for
30 min. A) MF4-mediated inhibition of PIKfyve causes the formation of swollen vacuoles that are inaccessible to internalized HRP. These
vacuoles are surrounded by a second class of smaller HRP-containing vacuoles. B) Both early and late endosomal markers are associated
with distinct swollen endosomes that surround these vacuoles. C) Retromer components Vps26 and SNX-1 also associate with swollen
endosomal compartments. Scale bars = 10 μm. D) The PtdIns 3-kinase inhibitor Wortmannin ablates endosomal PtdIns(3)P staining,
whilst MF4 treatment has no signiﬁcant effect. Scale bars = 20 μm. E) Chemical structure of MF4 (PIKfyve inhibitor) and MF2 (inactive
analogue).
application of PIKfyve inhibitor (Figure 5C, D and E). Flu-
orescence examination of EGFR distribution shows that
residual receptor following PIKfyve inhibition is concen-
trated in punctate structures which frequently co-localize
with the early endosomal marker EEA1 (29). In many
cases EGFR can be visualized in the interior of endo-
somes decorated with EEA1 on their limiting membrane
(Figure 5G). Thus acute pharmacological inhibition has
revealed an important function of PIKfyve in mammalian
cells that provides some reconciliation with data obtained
with Drosophilia knock-outs (21), which indicated defects
in receptor downregulation. If activated receptor was
retained at the limiting membrane of endosomes, one
may expect more prolonged signalling following acute
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Figure 2: Inhibition of PIKfyve causes a disruption in steady-state distribution of ciM6PR and TGN46. HeLa cells were treated
with 40 nM siRNA oligos for 72 h or 800 nMMF4 for 4 h. Both knockdown and inhibition of PIKfyve alter the steady-state localization of
ciM6PR, whereas Vac14 knockdown and MF2 (inactive analogue of the PIKfyve inhibitor MF4) have no effect (A and B). The markers
fragment into distinct vesicular compartments, which show little co-localization. The distribution of a second TGN resident protein
golgin-245 is unaffected and retains its characteristic perinuclear localization (D). The cis-golgi marker GM130 also retains it’s ribbon-like
disposition (E). There is no change in the levels of ciM6PR or retromer components upon treatment with PIKfyve inhibitor (F). Scale
bars = 20 μm.
activation (30). We do not see this when we examine
activation of mitogen-activated protein kinase (MAPK) or
AKT/proteinkinaseB(PKB).Ratherweseeadampeningof
AKT signalling at later time-points, e.g. 30 min (Figure 5F).
Although IC50 values of MF4 (23 nM) and YM210636
(33 nM) are similar towards PIKfyve, we obtain less selec-
tivity over PtdIns 3-kinase p110α than that reported for
YM210636 (24). To be certain that the observed effects
on EGFR degradation were not as a result of p110α
inhibition, speciﬁc inhibitors for both p110α and β were
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Figure 3: PIKfyve inhibition causes a delay in CD8-ciM6PR and CD8-Furin retrieval. Uptake of CD8 antibody in HeLa M cell lines
stably expressing CD8-ciM6PR and CD8-Furin was examined following treatment of cells with 800 nMMF4 PIKfyve inhibitor. Both Furin
and ciM6PR retrieval to a trans-Golgi localization is delayed upon inhibition of PIKfyve (A). At the terminal uptake time-point, in cells
where TGN46 is highly fragmented, there is negligible co-localization with CD8-ciM6PR (B). Scale bars = 20 μm.
used. Both inhibitors caused a signiﬁcant reduction in
phosphorylation of AKT/PKB but had no effect on EGFR
degradation (data not shown). These results in combi-
nation with the observation that MF4 does not cause
a reduction in initial EGF-dependent phosphorylation of
AKT/PKB, suggest that the effects on EGFR degradation
are not due to a non-speciﬁc inhibition of class 1 PtdIns
3-kinases.
Role of PIKfyve in autophagy
PtdIns3P generated by the PtdIns 3-kinase Vps34 is
required for initial steps of autophagosome formation,
but the role of PtdIns(3,5)P2 is less well established. The
Atg18 gene in yeast binds both 3-phosphoinositides with
a preference for PtdIns(3,5)P2 (16). One signature for
the accumulation of autophagosomes is the enrichment
of a faster migrating form (LC3 II) of the autophagy
protein LC3, following its conjugation to phosphatidyl-
ethanolamine (31). Whilst, neither Vac14 nor PIKfyve
knockdown had any signiﬁcant inﬂuence on starvation-
induced accumulation of GFP-LC3-II (data not shown),
inhibitor treatment led to a signiﬁcant increase, as judged
biochemically (Figure 6A and B) and by the visualization
of GFP-labelled punctae (Figure 6C). Addition of the
PIKfyve inhibitor, MF4 did not signiﬁcantly increase the
accumulation of GFP-LC3 in the presence of leupeptin,
a condition in which the degradation of GFP in the
late endosome/autolysosome should be reduced. This
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Figure 4: PIKfyve inhibition causes a perturbation in the uptake of the Shiga toxin B-subunit. Uptake of the Shiga toxin B-subunit
was examined in HeLa cells using a Cy3-labelled StxB construct, following treatment with 800 nMMF4 PIKfyve inhibitor. Cy3-STxB
retrieval to a perinuclear localization is also delayed in cells treated with PIKfyve inhibitor (A), but ultimately reaches a TGN localization, as
judged by co-localization with golgin-245 (B). In cells where TGN46 is highly dispersed, co-localization with Cy3-STxB can be observed,
indicative of the fact that these two proteins may trafﬁc on a similar retrieval pathway (C). Scale bars = 20 μm.
indicates that MF4 treatment does not increase the rate
of formation of autophagosomes but instead interferes
with their consumption.
Discussion
Previous studies in mammalian cells have assessed
phenotypes arising from siRNA knockdown. These have
the following drawbacks; (i) PIKfyve has proven hard to
completely deplete, so that residual enzymatic activity
could provide enough PtdIns(3,5)P2 particularly if the
enzyme is controlled by a positive feedback loop, (ii) it is
not clear if phenotypes observed are because of loss of
enzyme activity or of some other function of the protein
and (iii) depletion is very gradual, so that any phenotype
may constitute a very indirect consequence of protein
loss over a prolonged time period. Nevertheless, these
studies and our current study, have shown that the
distribution of proteins which trafﬁc between the sorting
endosome and the TGN is perturbed (23). This result is
recapitulated by acute pharmacological inhibition. One of
these proteins is TGN-46, which, because it is also cycling
along this pathway cannot be reliably used as a TGN
marker under these conditions. Golgin-245, another TGN
marker, shows signiﬁcantly less perturbation following
PIKfyve inhibition. Dispersed TGN-46 punctae produced
by PIKfyve inhibition do not co-localize with golgin-245,
suggesting that TGN-46 may accumulate in another
compartment that forms part of its itinerary. Whilst
Jeffries et al.suggest that the steady-state distribution
of CI-M6PR is not drastically altered following treatment
with YM201636, their experiments were performed in a
different cell line (NIH3T3) and other assays for retrieval
on this pathway were not examined (24). In accordance
with our data, a recent study of Vac14 −/− mice showed
a similar defect in CI-M6PR distribution (22).
As well as the steady-state distribution, the kinetics of
transport from the cell surface via the endosome to the
TGN is delayed for several proteins (CD8-CI-M6PR, CD8-
Furin, Shiga Toxin), which may utilize retromer-dependent
(CD8-CI-M6PR, Shiga toxin) and retromer-independent
(CD8-Furin) sorting mechanisms from the endosome.
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Figure 5: Acute inhibition of PIKfyve affects downregulation of tyrosine kinase receptors. HeLa cells were treated with siRNA
oligos against the indicated proteins (A and B), or with 3 μM PIKfyve inhibitor (C and D) or the indicated doses of inhibitor (E).
Serum-starved cells were stimulated with 100 ng/mL EGF or HGF for the indicated times. A) Individual knockdown of PIKfyve or Vac14
did not affect the degradation of either EGFR or c-Met. B) A combined knockdown of PIKfyve with Vac14 caused a modest delay in
receptor downregulation. C) Treatment with PIKfyve inhibitor caused a severe delay in EGFR. D) c-Met downregulation. E) Concentration
dependence of MF4 on EGFR downregulation after 120 min EGF stimulation. F) pMAPK and pAKT signalling is not prolonged following
treatment with PIKfyve inhibitor, pAKT signalling is dampened at later time-points. α-tubulin is used as a protein loading control.
G) Immunoﬂuorescence images demonstrating the accumulation of EGFR in PIKfyve inhibitor and combined knockdown treated HeLa
cells. HeLa cells were transfected with 40 nM of the indicated oligos over 72 h, then serum-starved overnight, and following treatment
with 800 nM PIKfyve inhibitor (in place of siRNA treatment; where indicated), were stimulated with 100 ng/mL EGF for 4 h. Following
ﬁxation with 3% PFA in PBS cells were labelled with anti-EGFR and anti-EEA-1. A proportion of the EGFR can be seen in the interior of
swollen early endosomal compartments (G). Scale bars = 20 μm.
Interestingly, retrieval to the TGN is delayed and not
completely blocked following loss of PIKfyve activity,
suggesting that either cargo may trafﬁc on alternate, less
efﬁcient pathwaysor thatenzymatic activityis rate-limiting
for this process but not essential.
Knockdown of PIKfyve (23) or of Vac14 (this study)
does not signiﬁcantly affect EGFR degradation rates,
consistent with previous studies. This observation has
been difﬁcult to reconcile with knockout phenotypes in
model organisms which have suggested a critical role for
PIKfyve in receptor degradation and formation of terminal
lysosomes (20,21). We reasoned that in the circumstance
of incomplete depletion, combining Vac14 and PIKfyve
knockdown should suppress PtdIns(3,5)P2 to a greater
extent than PIKfyve alone. This condition revealed a
modest inhibition of EGFR degradation (Figure 4B),
suggesting a role for PtdIns(3,5)P2 synthesis, but with
a relatively low threshold value. Consistent with this
observation, pharmacological inhibition of PIKfyve, at con-
centrationswhichdonotproduceanymajorperturbationin
the levels of other 3-phosphoinositides, revealed a strong
block to both EGFR and c-Met downregulation, as judged
by western blotting and by immunoﬂuorescence. The
Figure 6: Inhibition of PIKfyve leads
to an increase in starvation-induced
GFP-LC3 lipidation. HEK293A cells sta-
bly transfected with GFP-LC3 were treated
with MF4 PIKfyve inhibitor or an inactive
analogue (MF2) for 4 h prior to replace-
ment of fresh growth medium (fed) or
Earles’ balanced salt solution (EBSS) for
2 h (starved). Cells were subsequently
lysed or processed for immunoﬂuores-
cence. A) Western blot on triplicate sam-
ples indicating the levels of GFP-LC3 I and
II in fed and starved cells upon treatment
with MF4 and with or without the pro-
tease inhibitor Leupeptin. B) Quantitative
analysis of the ratio of GFP-LC3 II to
total GFP-LC3 from A. PIKfyve inhibition
causes a statistically signiﬁcant (n = 3,
p < 0.01, T-test) accumulation of lipi-
dated GFP-LC3 upon starvation-induced
autophagy. C) Immunoﬂuorescence analy-
sis of GFP-LC3 II punctae formation fol-
lowing starvation-induced autophagy. The
accumulation of GFP-LC3 II positive punc-
tae can be observed following treatment
with PIKfyve inhibitor. Scale bars = 20 μm.
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appearance of EGFR in the interior of swollen endosomes
positive for EEA1 suggests that the major impediment
is not a defect in sorting to luminal vesicles, but may
reﬂect a failure of multivesicular bodies to fuse with the
degradative late endosome/lysosomal compartment.
A role for PtdIns3P in the formation of autophagosomes is
well established (32), but the part played by PtdIns(3,5)P2
is less clear. We observethat PIKfyveinhibition leads to an
accumulationof lipidatedGFP-LC3on punctatestructures,
characteristic of autophagosomes (33). This could reﬂect
an increased rate of production of autophagosomal
structures or a decreased rate of their consumption by
fusion with lysosomes. Taking this data together with the
observation of Jefferies et al., that autophagic breakdown
of proteins is reduced by PIKfyve inhibition (24), we
favour the second interpretation. Thus, both effects on
the autophagy pathway and of EGFR downregulation
could be explained by a common mechanism, through
which PIKfyve inhibition either renders an acceptor late
endosome/lysosome compartment refractory to fusion
or leads to a defect in the acidiﬁcation necessary for
lysosomaldegradation.Althoughnotquantitative,Acridine
Orange accumulation in endocytic punctae, indicative of
acidiﬁcation, is similar in both MF4-treated and control
cells, although it does not accumulate in the highly
swollen vacuoles which appear disconnected from the
endocytic pathway (data not shown). Two general models
can explain how PtdIns(3,5)P2 effects are mediated;
(i) by recruitment of effector molecules with speciﬁc lipid
binding domains and (ii) allosteric regulation of resident
endocytic proteins, e.g. enzyme or channel activity.
Although Svp1 in yeast is an authentic PtdIns(3,5)P2
sensor it is less clear for its mammalian orthologues WIPI-
1andWIPI-2.WIPI-1,likeSvp1canbindbothPtdIns3P and
PtdIns(3,5)P2 invitro(17)whilstthelipidbinding-properties
of WIPI-2 are unknown. Other candidate effector proteins
remain to be identiﬁed.
In summary, juxtaposition of siRNA knockdown of PIKfyve
with pharmacological inhibition links the observed siRNA
phenotype of disrupted endosome to TGN trafﬁcking, with
enzymatic activity. However, pharmacological inhibition
reveals further defects on the receptor degradation and
autophagy pathway, suggesting that relatively low levels
of PtdIns(3,5)P2 are permissive for these pathways.
Materials and Methods
Antibodies and other reagents
Rabbit polyclonal human Vac14 antibodies were raised by immunizing rab-
bitswiththeN-terminalaminoacidsofVac14(HLEVRHQRSGRGDHLDRR),
conjugated via a cysteine to Limulus polyphemus haemocyanin (Covance)
and afﬁnity puriﬁed on peptide columns. Sheep anti-TGN46, sheep anti-
GM130antibodiesandsheepanti-GFPweregenerousgiftsofVasPonnam-
balam (University of Leeds, UK) Francis Barr and Ian Prior (both University
of Liverpool, UK) respectively. Rabbit polyclonal anti-PIKfyve and anti-CI-
M6PR antibodies were generous gifts from Lois Weisman (University of
Michigan, USA) and Paul Luzio (Cambridge Institute of Medical Research,
UK). Mouse monoclonal anti-Met (25H2) antibody, rabbit monoclonal phos-
phorylated AKT (pAkt) (Ser 473) and mouse monoclonal phosphorylated
MAPK (pMAPK) (Thr 202, Tyr 204) antibodies were from Cell Signalling.
Monoclonal anti-EGFR R1 was from Cancer Research UK Laboratories
(CRUK) and goat polyclonal anti-EGFR 1005 were from Santa Cruz. Mouse
monoclonal anti-tubulin was from Sigma. Mouse monoclonal anti-golgin
245 (p230) antibody was from BD Biosciences. Rabbit polyclonal anti-EEA-
1 was previously described (4). Secondary antibodies were from Molecular
Probes and Licor Biosciences. HeLa M cell lines stably expressing CD8-CI-
M6PR and CD8-Furin along with mouse monoclonal CD8 antibody were
generous gifts from Matthew Seaman (Cambridge Institute of Medical
Research, UK). Puriﬁed mouse EGF was obtained from J. Smith, Liverpool,
UK. 2GL9 cells, HEK293A cells stably transfected with GFP-LC3 have been
previously described (34). GST-2xFYVE (Hrs) vector was a gift from Harald
Stenmark (35) Following production in bacteria it was isolated with Glu-
tathioneSepharoseandthenbiotinylatedwithSulfo-NHS-LC-Biotin(Pierce,
UK). Puriﬁed PIKfyve protein was a kind gift from Frank Cooke (UCL, UK).
Synthesis and characterization of MF4 and MF2
Synthesis of the PIKfyve inhibitor (hereafter designated MF4) and
its inactive analogue, MF2 is described below. PI-103 (36) (200 mg,
0.57 mmol) and 2,6-di-tert-butyl-4-methylpyridine (136 mg, 0.66 mmol)
were dissolved in CH2Cl2 (20 mL) and cooled on ice. Triﬂic anhydride
(0.3 mL, 0.63 mmol) was added drop-wise and the reaction was
warmed to room temperature. Further CH2Cl2 was added (10 mL)
and the reaction was allowed to proceed overnight. The solvent was
removed in vacuo and the product was puriﬁed by silica gel ﬂash
chromatography with 25% EtOAc:Hexanes to yield 67 mg (24% yield).
Liquid chromatography–electrospray ionisation–mass spectrometry (LC-
ESI-MS) [MH]+ m/z calculated for C20H15F3N4O5S 481.1, found 480.9.
This product (67 mg, 0.14 mmol), cesium carbonate (64 mg, 0.20 mmol)
and nicotinamide (21 mg, 0.17 mmol) were added to dioxane (4 mL).
Xantphos (10 mg, 0.016 mmol) and Pd2(dba)3 (5 mg, 0.006 mmol) were
added and the reaction was heated to 100◦C for 24 h (37). The reaction
was diluted with CH2Cl2, ﬁltered and the solvent was removed in vacuo.
The product was puriﬁed by silica gel chromatography using a gradient
of 2–3% MeOH:CH2Cl2 and by reverse phase high performance liquid
chromotography (HPLC) using a MeCN/H2O/0.1% triﬂuoroacetate (TFA)
solvent system to give a white solid. LC-ESI-MS [MH]+ m/z calculated
for C25H20N6O3453.2, found 453.0. MF2 was prepared similarly using
PIK-112 (36) in place of PI-103. LC-ESI-MS [MH]+ m/z calculated for
C26 H22N6O2451.2, found 451.4.
In vitro kinase assay
Puriﬁed GST-PIKfyve bound to 5 μL of glutatione beads was incubated
with inhibitors at fourfold dilutions over a concentration range of 5 μM to
0.001 μM in a total reaction volume of 25 μL. The assay buffer contained
10 μM ATP, 2 μCi of (γ-32P) ATP, 100 μM PI-3P, 400 μM phosphatidyl-
ethanolamine, 25 mM HEPES (pH 7.4), 120 mM NaCl, 1.5 mM MgCl2,1m M
DTT, 0.5 mg/mL BSA and 2% dimethyl sulphoxide (DMSO). Reactions
were terminated by spotting onto nitrocellulose membranes, which were
then washed ﬁve or six times to remove unbound radioactivity and dried.
Transferredradioactivitywas quantitatedusingphosphorimaging,and IC50
values were calculated by ﬁtting the data to a sigmoidal dose-response
using Prism (GraphPad).
Cell culture, PIKfyve inhibitor treatment and siRNA
transfection
HeLa and HEK293A cells were cultured in 5% CO2 in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% foetal calf serum and
1% non-essential amino acids. To retain expression of stably transfected
constructs, culture medium for CD8 cell lines was supplemented with
0.5 mg/mLG418. On-Target Plus siRNA oligos against PIKfyve and Vac14
were purchased from Dharmacon. A 2-hit protocol over 72 h was used.
Brieﬂy, HeLa cells were seeded in six-well plates at a density of 2.4 × 105
cells/well. Cells were transfected with 40 nM of the corresponding oligo
using oligofectamine (Invitrogen), 24 h later. After a further 24 h, cells
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were reseeded onto six-well plates at the same density or onto cover-lips
at a density of 0.12 × 106 cells/well and transfected again with 40 nM
oligos for 24 h. Cells were then processed for western blotting and
immunoﬂuorescence as described below.
Growth factor stimulation and cell lysis
Where indicated, cells were serum-starved for 16 h and then stimulated
with 100 ng/mL EGF or hepatocyte growth factor (HGF). Cells were
washed twice in ice-cold phosphate buffered saline solution and lysed
in Nonidet P-40 lysis buffer (0.5% Nonidet P-40, 25 mM Tris/Cl, pH 7.5,
100 mM NaCl). Lysates were cleared by centrifugation, resuspended in 5×
SDS-samplebufferandresolvedbySDS-PAGEfollowedbyimmunoblotting
for detection with a Licor Odyssey.
Immunoﬂuorescence
Cells were processed for immunoﬂuorescence by ﬁxation in 3%
paraformaldehyde (PFA) in PBS, permeabilized with 0.2% Triton-X-100,
blocked in 0.2% ﬁsh skin gelatin in PBS and incubated with antibodies in
blockingbuffer.SecondaryantibodieswereconjugatedtoeitherAlexaFluor
488,594or633.Cover-slipswereimagedusingaLeicaconfocalSP2AOBS
(HCX PL APO CS 63.0 × 1.40 oil objective).
HRP Internalization and Electron microscopy (EM)
Cells were incubated in 10 mg/mL HRP in serum-free medium at 37◦Cf o r
10 min, 1 h or 4 h. Subsequently, cells were washed three times in ice-
cold PBS and ﬁxed in 0.5% glutaraldehyde for 30 min. Cells were washed
three times at room temperature with 0.1 M Tris-Cl pH 7.6, followed
by incubation for 10 min in 0.1% diaminobenzidine (DAB, Sigma) in Tris
buffer and then for 10 min in 0.1% DAB and 0.01% H202 in Tris buffer at
room temperature in the dark. The reaction was terminated, by washing
3 × 5 min in Tris buffer, and then 2 × 5 min in PBS. Cells were then post-
ﬁxed in the dark on ice with 1% OsO4 in 0.1 M phosphate buffer pH 7.4
for 1 h. Subsequently, the cells were washed 3 × 30 mi in PBS, followed
by 2 × 30 min in distilled water and then incubated in 5% uranyl acetate
in 30% ethanol for 1 h. Samples were dehydrated by sequential 10-min
ethanol washes in 30%, 60%, 70%, 80% and then twice in 100% ethanol,
then inﬁltrated with a 1:1 ratio of resin to 100% ethanol for 30 min. The
inﬁltration resin was then replaced with 100% resin and the ﬂat-embedded
samples were polymerized at 60◦C for 2 to 3 days.
Anti-CD8 uptake experiments
HeLaM CD8-CIM6PR or CD8-Furin cells were seeded onto cover-slips
and treated with either siRNA or PIKfyve inhibitor. Cover-slips were then
transferred to a well containing 3 mL ice-cold dihydroxybenzoate (DHB)
(DMEM containing25 mM Hepes and 0.2% fatty-acid free BSA) for 15 min.
CD8-CIM6PR and CD8-Furin receptors at the cell surface were labelled by
placing cover-slips, cell side down, upon a 100 μL drop of DHB containing
1 μg monoclonal anti-CD8 antibody at 4◦C, for 1 h. Cover-slips were
washed twice in ice-cold PBS, and then transferred to pre-warmed growth
medium for the indicated time periods to allow uptake of the anti-CD8
antibody to occur. At the assay endpoint, cells were ﬁxed and processed
for immunoﬂuorescence as described earlier.
Shiga toxin uptake assay
The assay has been described previously (38). Brieﬂy, HeLa cells were
seeded onto cover-slips and treated with either siRNA or PIKfyve inhibitor
as described earlier. Subsequently, cells were incubated on ice for 30 min
with 2 μg/μL Cy3-STxB in DHB. The 0-min time-point was immediately
ﬁxed and the remaining cover-slips washed twice in ice-cold PBS,
transferred to pre-warmed growth medium and returned to the incubator
for the indicated time periods to allow uptake to proceed. At the assay
endpoint, cells were ﬁxed and processed for immunoﬂuorescence as
described earlier.
Induction of autophagy and GFP-LC3 shift assay
HEK293A cells stably expressing GFP-LC3 were seeded onto 12-well
plates and treated with siRNA or PIKfyve inhibitor as described above.
To induce autophagy the growth medium was either replaced with fresh
medium (fed) or cells were washed four times with Earl’s buffered saline
solution and then starved for 2 h in the ﬁnal wash. Where indicated,
Leupeptin was added to the starvation medium at a concentration of
0.25 mg/mL. Following starvation, cells were either ﬁxed and processed
for immunoﬂuorescence or lysed in 1× SDS-sample buffer. After protein
determination lysates were supplemented with 1 mM DTT and 0.1%
bromophenol blue and resolved by SDS-PAGE for western blotting with
polyclonal sheep anti-GFP antibodies, which were quantiﬁed using a Licor
Odyssey instrument.
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